Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan
NCT05132127
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
7
Enrollment
INDUSTRY
Sponsor class
Conditions
Cold Agglutinin Disease
Interventions
DRUG:
sutimlimab
Sponsor
Sanofi